Why the study?
Does ticagrelor improve anti-ischemic protection without increasing major bleeding compared to clopidogrel in real-world Taiwanese patients with acute myocardial infarction?
Does ticagrelor improve anti-ischemic protection without increasing major bleeding compared to clopidogrel in real-world Taiwanese patients with acute myocardial infarction?
In a real-world Taiwanese AMI cohort, ticagrelor appeared to provide superior anti-ischemic efficacy compared to clopidogrel without increasing the risk of major bleeding.
Answers are grounded in this paper and cite their sources.
May support ticagrelor preference in real-world Taiwanese AMI; hypothesis-generating and requires randomized confirmation.
In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: